Linked Life Data

16556011

Source:http://linkedlifedata.com/resource/pubmed/id/16556011

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-3-24
pubmed:abstractText
A significant number of tumor patients fail peripheral blood progenitor cell (PBPC) mobilization and thus cannot receive potentially curative high-dose chemotherapy with subsequently required PBPC transplantation. New insights into the physiology of mobilization have revealed the pivotal role of the CXCR4/stromal derived factor-1alpha receptor-ligand interaction for stem cell retention in the bone marrow. New CXCR4 antagonists such as AMD3100 are currently in clinical studies. They act synergistically with the established mobilizing agent granulocyte colony-stimulating factor (G-CSF); thus, patients can collect more PBPCs in fewer apheresis sessions, and others that previously failed can now successfully collect sufficient PBPCs for transplantation. Experimental and clinical data suggest that the quality of AMD3100-mobilized PBPC may even be superior to PBPCs mobilized following standard therapy. CXCR4 antagonists are the most exciting development in the field of PBPC mobilization for over a decade. Additionally, new analogs of G-CSF are being introduced with favorable pharmacologic features.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1479-6694
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-83
pubmed:dateRevised
2006-7-3
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
New strategies for mobilization of hematopoietic stem cells.
pubmed:affiliation
University of Heidelberg, Department of Internal Medicine V, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. stefan_fruehauf@med.uni-heidelberg.de
pubmed:publicationType
Journal Article, Review